First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel–Lindau (VHL) disease

clinical outcome and patterns of radiological response

Anna Roma, Marco Maruzzo, Umberto Basso, Antonella Brunello, Rita Zamarchi, Elisabetta Bezzon, Fabio Pomerri, Stefania Zovato, Giuseppe Opocher, Vittorina Zagonel

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

von Hippel–Lindau (VHL) is a rare hereditary condition caused by germline alteration of VHL gene predisposing to renal carcinoma and multiple other tumors. Since acquired dysregulation of VHL-dependent pathways is often present in patients with sporadic RCC treated with the anti-angiogenic drug sunitinib, there is a strong rationale to use the same drug in VHL patients with progressive disease in the kidneys or other sites. Our primary objective was to evaluate the activity of sunitinib in terms of progression-free survival. Secondary objectives: rate of radiological response, patterns of responses in different organs, treatment-related toxicities. We performed a retrospective analysis of sunitinib therapy in genetically-confirmed VHL patients treated at our Institution for multifocal or advanced RCC. From February 2007 to July 2012, 14 VHL patients started first-line sunitinib for recurrent or progressing RCC, mean age 48 years (27–71). Nine patients achieved a partial RECIST response (64.3 %); responses were noted not only in renal and hepatic lesions but also in pancreatic nodules. Most lesions showed density reduction, while all CNS haemangioblastoma lesions remained stable. At a median follow-up of 37 months, six patients have progressed and three patients died, with a progression-free rate at 2 years of 71.4 %. Sunitinib may therefore achieve a fairly good disease control in VHL patients. Radiological responses may be obtained not only in renal tumors but also in synchronous VHL-related lesions, especially pancreatic solid nodules whose exact nature (metastatic RCC or neuroendocrine tumor) cannot be ruled out without invasive biopsy.

Original languageEnglish
Pages (from-to)309-316
Number of pages8
JournalFamilial Cancer
Volume14
Issue number2
DOIs
Publication statusPublished - Nov 13 2014

Fingerprint

Renal Cell Carcinoma
Kidney
Hemangioblastoma
Angiogenesis Inhibitors
Neuroendocrine Tumors
sunitinib
Kidney Diseases
Disease-Free Survival
Neoplasms
Carcinoma
Biopsy
Liver
Therapeutics
Pharmaceutical Preparations
Genes

Keywords

  • Renal cell carcinoma
  • Sunitinib
  • von Hippel–Lindau (VHL)

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Oncology
  • Genetics(clinical)

Cite this

@article{10a19b464b2140afa86775d0049a520a,
title = "First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel–Lindau (VHL) disease: clinical outcome and patterns of radiological response",
abstract = "von Hippel–Lindau (VHL) is a rare hereditary condition caused by germline alteration of VHL gene predisposing to renal carcinoma and multiple other tumors. Since acquired dysregulation of VHL-dependent pathways is often present in patients with sporadic RCC treated with the anti-angiogenic drug sunitinib, there is a strong rationale to use the same drug in VHL patients with progressive disease in the kidneys or other sites. Our primary objective was to evaluate the activity of sunitinib in terms of progression-free survival. Secondary objectives: rate of radiological response, patterns of responses in different organs, treatment-related toxicities. We performed a retrospective analysis of sunitinib therapy in genetically-confirmed VHL patients treated at our Institution for multifocal or advanced RCC. From February 2007 to July 2012, 14 VHL patients started first-line sunitinib for recurrent or progressing RCC, mean age 48 years (27–71). Nine patients achieved a partial RECIST response (64.3 {\%}); responses were noted not only in renal and hepatic lesions but also in pancreatic nodules. Most lesions showed density reduction, while all CNS haemangioblastoma lesions remained stable. At a median follow-up of 37 months, six patients have progressed and three patients died, with a progression-free rate at 2 years of 71.4 {\%}. Sunitinib may therefore achieve a fairly good disease control in VHL patients. Radiological responses may be obtained not only in renal tumors but also in synchronous VHL-related lesions, especially pancreatic solid nodules whose exact nature (metastatic RCC or neuroendocrine tumor) cannot be ruled out without invasive biopsy.",
keywords = "Renal cell carcinoma, Sunitinib, von Hippel–Lindau (VHL)",
author = "Anna Roma and Marco Maruzzo and Umberto Basso and Antonella Brunello and Rita Zamarchi and Elisabetta Bezzon and Fabio Pomerri and Stefania Zovato and Giuseppe Opocher and Vittorina Zagonel",
year = "2014",
month = "11",
day = "13",
doi = "10.1007/s10689-014-9771-y",
language = "English",
volume = "14",
pages = "309--316",
journal = "Familial Cancer",
issn = "1389-9600",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel–Lindau (VHL) disease

T2 - clinical outcome and patterns of radiological response

AU - Roma, Anna

AU - Maruzzo, Marco

AU - Basso, Umberto

AU - Brunello, Antonella

AU - Zamarchi, Rita

AU - Bezzon, Elisabetta

AU - Pomerri, Fabio

AU - Zovato, Stefania

AU - Opocher, Giuseppe

AU - Zagonel, Vittorina

PY - 2014/11/13

Y1 - 2014/11/13

N2 - von Hippel–Lindau (VHL) is a rare hereditary condition caused by germline alteration of VHL gene predisposing to renal carcinoma and multiple other tumors. Since acquired dysregulation of VHL-dependent pathways is often present in patients with sporadic RCC treated with the anti-angiogenic drug sunitinib, there is a strong rationale to use the same drug in VHL patients with progressive disease in the kidneys or other sites. Our primary objective was to evaluate the activity of sunitinib in terms of progression-free survival. Secondary objectives: rate of radiological response, patterns of responses in different organs, treatment-related toxicities. We performed a retrospective analysis of sunitinib therapy in genetically-confirmed VHL patients treated at our Institution for multifocal or advanced RCC. From February 2007 to July 2012, 14 VHL patients started first-line sunitinib for recurrent or progressing RCC, mean age 48 years (27–71). Nine patients achieved a partial RECIST response (64.3 %); responses were noted not only in renal and hepatic lesions but also in pancreatic nodules. Most lesions showed density reduction, while all CNS haemangioblastoma lesions remained stable. At a median follow-up of 37 months, six patients have progressed and three patients died, with a progression-free rate at 2 years of 71.4 %. Sunitinib may therefore achieve a fairly good disease control in VHL patients. Radiological responses may be obtained not only in renal tumors but also in synchronous VHL-related lesions, especially pancreatic solid nodules whose exact nature (metastatic RCC or neuroendocrine tumor) cannot be ruled out without invasive biopsy.

AB - von Hippel–Lindau (VHL) is a rare hereditary condition caused by germline alteration of VHL gene predisposing to renal carcinoma and multiple other tumors. Since acquired dysregulation of VHL-dependent pathways is often present in patients with sporadic RCC treated with the anti-angiogenic drug sunitinib, there is a strong rationale to use the same drug in VHL patients with progressive disease in the kidneys or other sites. Our primary objective was to evaluate the activity of sunitinib in terms of progression-free survival. Secondary objectives: rate of radiological response, patterns of responses in different organs, treatment-related toxicities. We performed a retrospective analysis of sunitinib therapy in genetically-confirmed VHL patients treated at our Institution for multifocal or advanced RCC. From February 2007 to July 2012, 14 VHL patients started first-line sunitinib for recurrent or progressing RCC, mean age 48 years (27–71). Nine patients achieved a partial RECIST response (64.3 %); responses were noted not only in renal and hepatic lesions but also in pancreatic nodules. Most lesions showed density reduction, while all CNS haemangioblastoma lesions remained stable. At a median follow-up of 37 months, six patients have progressed and three patients died, with a progression-free rate at 2 years of 71.4 %. Sunitinib may therefore achieve a fairly good disease control in VHL patients. Radiological responses may be obtained not only in renal tumors but also in synchronous VHL-related lesions, especially pancreatic solid nodules whose exact nature (metastatic RCC or neuroendocrine tumor) cannot be ruled out without invasive biopsy.

KW - Renal cell carcinoma

KW - Sunitinib

KW - von Hippel–Lindau (VHL)

UR - http://www.scopus.com/inward/record.url?scp=84937867062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937867062&partnerID=8YFLogxK

U2 - 10.1007/s10689-014-9771-y

DO - 10.1007/s10689-014-9771-y

M3 - Article

VL - 14

SP - 309

EP - 316

JO - Familial Cancer

JF - Familial Cancer

SN - 1389-9600

IS - 2

ER -